Coherent, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Plans for a secondary offering of 3 mil. shares of common stock are outlined in a registration statement filed with the SEC. Santa Clara, California-based Coherent, which gained FDA approval in April for its Opal Photoactivator laser for use in photodynamic therapy with QLT PhotoTherapeutics' Visudyne (verteporfin for injection) to treat "wet" age-related macular degeneration (1"The Gray Sheet" April 17, In Brief), says it plans to use the proceeds "for acquisitions of and investments in businesses, technologies and products, continued development of new technologies and general corporate purposes." Underwriters UBS Warburg, CIBC World Markets, U.S. Bancorp Piper Jaffray and BlueStone Capital Partners will have an option for up to 450,000 overallotment shares
You may also be interested in...
QLT PhotoTherapeutics
FDA approval of Visudyne (verteporfin for injection) to treat "wet" age-related macular degeneration in conjunction with lasers made by Coherent and Zeiss Humphrey Systems to activate the photodynamic therapy is announced April 13. Independent marketing of Coherent's Opal Photoactivator and Zeiss' Visulas 690 PDT lasers, which have only slightly different features, commenced immediately following approval. The Opal is priced in the $40,000-50,000 range and the Visulas is priced at $37,900-44,900, depending on configuration with or without a slitlamp
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.